Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

inmunotek - aspergillus fumigatus allergen extract - solution for skin-prick test

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - aspergillus niger, quantity: 1 ml/ml (equivalent: aspergillus niger, qty 100 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - aspergillus fumigatus, quantity: 1 ml/ml (equivalent: aspergillus fumigatus, qty 100 mg/ml) - extract, liquid - excipient ingredients: glycerol; sodium chloride; sodium bicarbonate; water for injections - indicated use of allergenic extracts is for the diagnosis and treatment (hypo-sensitization therapy) of patients who experience allergic symptoms.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

uspharmaco - mucor racemosus 4x and aspergillus niger 4x - for temporary relief from symptoms of sore throat

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bio-rad laboratories pty ltd - ct937 - aspergillus ivds - microplate assays intended to be used in vitro diagnostic detection of species from the fungus aspergillus in biological samples.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - aspergillus fumigatus 0.05 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

nelco laboratories, inc. - aspergillus fumigatus (unii: x88df51t48) (aspergillus fumigatus - unii:x88df51t48) - aspergillus fumigatus 0.1 g in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bruker pty ltd - ct937 - aspergillus ivds - the fungiplex aspergillus ivd real-time pcr kits are multiplex polymerase chain reaction (pcr) in vitro diagnostic (ivd) test for the qualitative detection of aspergillus dna extracted from edta whole blood, edta plasma, serum and bronchoalveolar lavage (bal) fluid obtained from human patients considered at risk of invasive fungal disease (ifd) and for use in conjunction with other clinical and laboratory findings to aid the rapid detection of aspergillus azole resistance markers in serum, plasma, bronchoalveolar lavage (bal) and directly from clinical isolates. the tests are intended for use by qualified laboratory individuals as an aid to the diagnosis of invasive aspergillosis, specifically of aspergillus spp. and a. terreus infections and upon a positive result as an aid to the stratification and guidance on available treatment options of patients infected by aspergillus fumigatus with the specific mutations of the cyp51a gene.the results of these tests should not be used as the sole basis for diagnosis, treatment or patient management decisions.

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

alk-abello ltd - aspergillus fumigatus allergen extract - solution for skin-prick test